Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final up...
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
About this item
Full title
Author / Creator
ERIVANCE BCC Investigators , for the ERIVANCE BCC Investigators , Sekulic, Aleksandar , Migden, Michael R , Basset-Seguin, Nicole , Garbe, Claus , Gesierich, Anja , Lao, Christopher D , Miller, Chris , Mortier, Laurent , Murrell, Dedee F , Hamid, Omid , Quevedo, Jorge F , Hou, Jeannie , McKenna, Edward , Dimier, Natalie , Williams, Sarah , Schadendorf, Dirk and Hauschild, Axel
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review...
Alternative Titles
Full title
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Authors, Artists and Contributors
Author / Creator
for the ERIVANCE BCC Investigators
Sekulic, Aleksandar
Migden, Michael R
Basset-Seguin, Nicole
Garbe, Claus
Gesierich, Anja
Lao, Christopher D
Miller, Chris
Mortier, Laurent
Murrell, Dedee F
Hamid, Omid
Quevedo, Jorge F
Hou, Jeannie
McKenna, Edward
Dimier, Natalie
Williams, Sarah
Schadendorf, Dirk
Hauschild, Axel
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_369c8eef082e487e8b1ee700e6160944
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_369c8eef082e487e8b1ee700e6160944
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-017-3286-5
